The objective of this study was to demonstrate the feasibility and the relevance of combining biochar with the Fenton process for the simultaneous improvement of polycyclic aromatic hydrocarbons (PAHs) degradation and immobilization of heavy metals (HMs) in real soil remediation processes at circumneutral pH. The evaluation of PAHs degradation results was performed through multivariate statistical tools, including principal component analysis (PCA) and partial least squares (PLS). PCA showed that the level of biochar amendment decisively affected the degree of degradation of total PAHs, highlighting the role of biochar in catalyzing the Fenton reaction. Moreover, the PLS model was used to interpret the important features of each PAH's physico-chemical properties and its correlation to degradation efficiency. The electron affinity of PAHs correlated positively with the degradation efficiency only if the level of biochar amendment sat at 5%, explained by the ability of biochar to transfer the electrons to PAHs, improving the Fenton-like degradation. Moreover, the addition of biochar reduced the mobilization of HMs by their fixation on their surface, reducing the Fenton-induced metal leaching from the destruction of metal-organic complexes. In overall, these results on the high immobilization rate of HMs accompanied with additional moderate PAHs degradation highlighted the advantages of using a biochar-assisted Fenton-like reaction for sustainable remediation of technogenic soil.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.envpol.2022.119096 | DOI Listing |
Oncol Res
January 2025
Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.
Background: Hepatocellular carcinoma (HCC) is a health problem due to multi-drug resistance (MDR). Codelivery of multiple oncotherapy in one cargo as chimeric cancer therapy (CCT) is suggested as a solution for MDR. This study aims to engineer chitosan-coated nanostructure lipid carriers (NLCs) loaded with gefitinib (GF) and simvastatin (SV) as CCT for HCC.
View Article and Find Full Text PDFJ Biochem Mol Toxicol
February 2025
Department of Cardiology, Affiliated Hospital of Hebei University, Baoding, China.
Ischemia-reperfusion (I/R) injury is a significant clinical problem impacting the heart and other organs, such as the kidneys and liver. This study explores the protective effects of oxycodone on myocardial I/R injury and its underlying mechanisms. Using a myocardial I/R model in Sprague-Dawley (SD) rats and an oxygen-glucose deprivation/reoxygenation (OGD/R) model in H9c2 cells, we administered oxycodone and inhibited AMP-activated protein kinase (AMPK) with Compound C (C.
View Article and Find Full Text PDFTechnol Cancer Res Treat
January 2025
Cell Therapy Center, The University of Jordan, Amman, Jordan.
Background: Doxorubicin (DOX) is a potent chemotherapeutic agent for breast cancer, but its effectiveness is often diminished by resistance mechanisms, particularly through p-glycoprotein (P-gp) mediated drug efflux. Clarithromycin (CAM), a macrolide antibiotic, inhibits multiple metabolic pathways including CYP3A and P-gp, potentially countering DOX resistance.
Objective: This study aimed to evaluate the potentiation of DOX and its effectiveness against the MCF-7 breast cancer cell line by encapsulating both DOX and CAM in PEGylated liposomes.
J Comput Chem
January 2025
Regional Center of Advanced Technologies and Materials, Czech Advanced Technology and Research Institute (CATRIN), Palacký University Olomouc, Olomouc, Czech Republic.
Doxorubicin (DOX) is a widely used chemotherapeutic agent known for intercalating into DNA. However, the exact modes of DOX interactions with various DNA structures remain unclear. Using molecular dynamics (MD) simulations, we explored DOX interactions with DNA duplexes (dsDNA), G-quadruplex, and nucleosome.
View Article and Find Full Text PDFPharmacol Res Perspect
February 2025
Department of Pharmaceutical Health Care and Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Doxorubicin (DOXO) has long been used clinically and remains a key drug in cancer therapy. DOXO-induced cardiomyopathy (DICM) is a chronic and fatal complication that severely limits the use of DOXO. However, there are very few therapeutic agents for DICM, and there is an urgent need to identify those that can be used for a larger number of patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!